Aclaris reports Q3 2026 results, positive ATI-052 data, and 2029 cash runway
The company reaffirmed upcoming bosakitug and modzatinib milestones and said it expects cash to last through the first half of 2029.
Aclaris Therapeutics announced financial results for the third quarter of 2026 along with a corporate and clinical update on November 5, 2026, covering its pipeline across biologics and kinase inhibitors.
The company reported positive primary analysis results from Phase 1b proof-of-concept trials of its bispecific anti-TSLP/IL-4Rα antibody ATI-052 in both atopic dermatitis and asthma. In the AD trial, patients treated with ATI-052 experienced a 45% placebo-adjusted mean change in EASI score from baseline at week 8, with durable responses seen through week 16 in the subset of patients with available data, and a 78% placebo-adjusted EASI-50 at week 8.1 Patients also saw a 43% placebo-adjusted improvement in itch scores at week 8, and the drug was well tolerated with no conjunctivitis observed.1 In the asthma trial, a single dose produced a 59% mean absolute reduction in fractional exhaled nitric oxide at day 15, a 40% reduction at day 29, and a placebo-adjusted 200 ml improvement in FEV1 at day 15.1
Based on these results, Aclaris said it will prioritize Phase 2b development of ATI-052 first in eosinophilic esophagitis, with an assessment of a second indication, either AD or asthma, expected shortly.1 The company also reaffirmed that top line results from the Phase 2 ADMIRATION trial of bosakitug in 109 patients with moderate-to-severe atopic dermatitis are expected in the fourth quarter of 2026.1 Separately, startup activities for a Phase 2b trial of modzatinib in lichen planus are underway, with first site activation expected in November 2026.1 An IND filing for ATI-9494, a dual ITK/TXK inhibitor, remains on track for the fourth quarter of 2026, according to the release.
On finances, Aclaris held $204.6 million in cash, cash equivalents and marketable securities as of September 30, 2026, up from $151.4 million at year-end 2025.1 In October 2026, the company raised $50.0 million in gross proceeds through a stock and pre-funded warrant offering.1 Including those proceeds, Aclaris said its cash position should fund operations through the first half of 2029.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.